Predictors of liver fibrosis changes assessed by paired liver biopsies in chronic hepatitis C patients treated with direct-acting antivirals
For DAA-treated CHC patients, those with baseline age <65 years, fibrosis stages <3, hemoglobin levels ≥12.5 g/dL, or platelet counts ≥160 10<sup>3</sup>/μL are more likely to attain fibrosis regression. There is a higher risk of fibrosis progression in those with baseline age ≥66 years, BMI ≥26.5 kg/m<sup>2</sup>, sofosbuvir/ribavirin use, platelet counts <119 10<sup>3</sup>/μL, or the absence of early ALT normalization at 4 weeks after baseline.
Authors
- Ming-Han Hsieh (ORCID: https://orcid.org/0000-0001-9751-6692)
- Cheng‐Yuan Peng (ORCID: https://orcid.org/0000-0001-9030-6086)
- Jung‐Ta Kao (ORCID: https://orcid.org/0000-0002-3801-5342)
- Hsueh‐Chou Lai (ORCID: https://orcid.org/0000-0002-0126-6447)
- Ting–Hui Hsieh
- C.- H. Kao
- Tzu-Yu Kao
- Hsing-Hung Cheng
- Mao‐Wang Ho
Institutions
- National Yang Ming Chiao Tung University (TW)
- China Medical University (TW)
- China Medical University Hospital (TW)
Publication Details
- Journal
- Journal of Microbiology Immunology and Infection
- Published
- 2024-08-15
- DOI
- https://doi.org/10.1016/j.jmii.2024.08.005
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00